[Antiangiogenic treatment for neovascular glaucoma and after filtering surgery]

J Lüke, M Lüke, S Grisanti
Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2009, 106 (5): 407-12
Bevacizumab is increasingly discussed as adjuvant treatment for rubeosis and for all stages of neovascular glaucoma. In incipient rubeosis bevacizumab has a preventive effect and arrests the progression of disease. In the case of increasing involvement of the anterior chamber angle, bevacizumab should be integrated into stage-adapted treatment to achieve successful control of intraocular pressure. The treatment of the causative ischemic stimulus is necessary in every stage of disease. One further indication for bevacizumab is the postoperative inhibition of angiogenesis after glaucoma surgery. Possible routes of administration are subconjunctival application during trabeculectomy, postoperative needling, or intravitreal injection during a filtrating operation. This review summarizes results of current studies about bevacizumab for rubeosis, neovascular glaucoma, or filtrating surgery and adds future perspectives for possible therapeutic schemes.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.